Sanovas Recognized for its Breakthrough Endoscopic Imaging MicroCam™ Platform

-- The company receives the 2014 Frost &Sullivan New Product Innovation Leadership Award for its novel tool that addresses complex challenges in healthcare delivery

MOUNTAIN VIEW, California, Dec. 1, 2014 /PRNewswire/ -- Based on its recent analysis of the endoscopic imaging market, Frost & Sullivan recognizes Sanovas Inc. with the 2014 Global Frost & Sullivan Award for New Product Innovation Leadership. In a market where spiralling healthcare costs impact the entire spectrum of stakeholders, Sanovas's ground-breaking endoscopic platform, MicroCam™, provides the functionality of a high-end, flexible endoscope without the accompanying cost and maintenance burden.

Photo - http://photos.prnewswire.com/prnh/20141125/160976

The configuration of the MicroCam system leverages technical developments in image processing software and hardware to reimagine how minimally invasive visualization is performed. Distilling the technology to its core function of image capture and analysis has allowed Sanovas to pioneer a markedly more efficient approach for minimally invasive visualization. This solution has the potential to provide an unprecedented degree of versatility in both the clinical applications and care settings where endoscopic imaging can be employed.

"MicroCam removes the need for a cart-based console and its associated components," said Frost & Sullivan Research Analyst Venkat Rajan. "A true 'plug-and-play' solution, the innovative MicroCam's construct allows it to be easily connected to computing devices such as laptops, tablets, or computers."

Beyond its standalone uses for endoscopy, the profile and cost of Sanovas's solution enable integration with other minimally invasive tools. Often, care providers must run a scope, remove the scope, and then insert another tool for treatment. In many other cases, clinicians might have to diagnose based on external symptoms and then perform a corrective procedure without visual support. The ability to physically integrate the MicroCam with another system mitigates such guesswork and facilitates timely, accurate care.

To its credit, Sanovas is making this solution available to other medical technology developers. This collaborative approach is notable in an industry that has traditionally preferred to develop end-to-end solutions in-house. By opening doors to other stakeholders in the industry, Sanovas is expanding the potential applications of MicroCam to a multitude of existing and future treatment tools.

"The MicroCam platform possesses the potential to not only redefine the economics of endoscopy in North America, but to extend access to minimally invasive surgery for billions of patients globally," added Rajan. "For its pioneering approach, Sanovas has rightly earned the 2014 Global Frost & Sullivan New Product Innovation Leadership Award in endoscopic imaging."

Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value-added features/benefits of the product and the increased ROI it offers customers, which, in turn, increases customer acquisition and overall market penetration potential.

Frost & Sullivan's Best Practices Awards recognize companies in a variety of regional and global markets for outstanding achievement in areas such as leadership, technological innovation, customer service, and product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research.

About Sanovas Inc.

At the heart of the Sanovas companies' scientific advances is the miniaturization of tools for minimally invasive surgery, or "M-I-S." Its products extend access beyond current limits, enabling physicians to diagnose and perform therapeutic interventions in spaces as small as one millimeter in diameter that have previously been unreachable. Sanovas expects to commercialize the technology in coordination with its various partners to address unmet clinical needs in Oncology, Pulmonology, Cardiology, Neurosurgery, ENT, GI, General Surgery, Urology and Gynecology.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies? Contact us: Start the discussion.

Contact:

Mireya Espinoza
P: +1.210.247.3870
F: +1.210.348.1003
E: mireya.espinoza@frost.com